— Know what they know.
Not Investment Advice

TRRI OTC

Alzex Neuropharma Inc.
1W: +0.0% 1M: +0.0% 3M: -66.7% YTD: +100.0% 1Y: -99.4% 3Y: -99.7% 5Y: -99.6%
$0.00
+0.00 (+0.00%)
 
OTC · Basic Materials · Other Precious Metals · Tech Score Neutral · Power 48 · $602 mcap · Short 50% of daily vol

Balance Sheet Trends

Total Assets
$20K +8857.5% ▲
5Y CAGR: -61.0%
Total Liabilities
$238K +349.3% ▲
5Y CAGR: -31.3%
Shareholders Equity
-$218K -313.9% ▼
Cash & Investments
$1K +365.8% ▲
5Y CAGR: -25.2%
Total Debt
$91K +0.0% ▲
5Y CAGR: -41.4%
Net Debt
$90K +41279.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2010FY2012FY2020FY2021FY2022
— Assets —
Cash$54K$523$39$219$1K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$54K$523$39$219$1K
Net Receivables$348K$0$0$0$13K
Inventory$0$0$0$0$0
Other Current Assets$21K$0$0$0$0
Total Current Assets$423K$523$39$219$19K
Property, Plant & Equip.$5K$0$0$0$0
Goodwill & Intangibles$1M$0$0$0$300
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$531K$32K$0$0$0
Total Non-Current Assets$2M$32K$0$0$300
Total Assets$2M$33K$39$219$20K
— Liabilities —
Accounts Payable$82K$0$0$0$0
Short-Term Debt$0$0$45K$0$91K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$139K$54K$30K$53K$146K
Total Current Liabilities$221K$54K$75K$53K$238K
Long-Term Debt$837K$80K$0$0$0
Other Non-Current Liab.$49K$0$0$0$0
Total Non-Current Liabilities$886K$80K$0$0$0
Total Liabilities$1M$134K$75K$53K$238K
— Equity —
Common Stock$0$715K$15$15$15
Retained Earnings$0-$858K-$846K-$824K-$989K
Accumulated OCI$0$0$0$771K$771K
Total Stockholders Equity$1M-$102K-$75K-$53K-$218K
Total Liabilities & Equity$2M$33K$39$219$20K
— Key Metrics —
Total Debt$837K$80K$45K$0$91K
Net Debt$783K$80K$45K-$219$90K
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms